EPAD paper reviews effects of disclosing AD biomarker results to healthy individuals

Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be returned to research participants and what the psychological, behavioural and social effects of disclosure are. A systematic review by the European Prevention of Alzheimer’s Dementia (EPAD)…

EPAD conference held in Switzerland

On 10 November 2016, the European Prevention of Alzheimer’s Dementia (EPAD) initiative held a public conference in Geneva, Switzerland, in collaboration with Hôpitaux universitaires de Genève (HUG). Approximately 100 delegates attended the French and English-language conference, “Prévenir la maladie d’Alzheimer en Suisse – Un but atteignable“ (Preventing Alzheimer’s disease in Switzerland – A realistic goal).…

Our new sister project AMYPAD officially launches today

Today, our new sister project Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) announces the launch of its novel research initiative, bringing together academic and private research partners to investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia. Beta-amyloid (β-amyloid) deposition in the brain is…

EPAD features prominently at AAIC Conference in Toronto

The Alzheimer’s Association International Conference took place in Toronto from 23 to 28 July. EPAD – funded by the Innovative Medicines Initiative (IMI) – featured in a number of key symposia and communications: At a joint pre-conference meeting of the Global Alzheimer’s Platform and EPAD on global Alzheimer’s research collaboration on 22 July, EPAD researchers…

EPAD recruits its first Spanish research participant

The European Prevention of Alzheimer’s Dementia initiative (EPAD) has recruited its first research participant in Spain, Maria (pictured). The EUR 64 million Europe-wide initiative, which aims to improve our understanding of the early stages of Alzheimer’s disease and how it leads to dementia, is building a registry of 24,000 people and a cohort of 6,000…

Barcelona, international meeting point for research on Alzheimer’s dementia prevention

The European Prevention of Alzheimer’s Dementia (EPAD) is an initiative that groups together 36 academic research centres & universities, biotech & pharmaceutical companies and patient associations with the aim of establishing an infrastructure to facilitate clinical trials to prevent the onset of the disease.  The first volunteers, from Edinburgh and Barcelona, are currently being incorporated…